Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 778, Issue , 2015, Pages 46-51

  Balgkouranidou, I ^a   Matthaios, D ^a   Karayiannakis, A ^a   Bolanaki, H ^a   Michailidis, P ^a   Xenidis, N ^a   Amarantidis, K ^a   Chelis, L ^a   Trypsianis, G ^a   Chatzaki, E ^a   Lianidou, E S ^b   Kakolyris, S ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

APC; Cell free DNA; DNA methylation; Gastric cancer; Prognosis; RASSF1A

Indexed keywords

DNA; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; RASSF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; APC GENE; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; GENE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RASSF1A GENE; STOMACH CANCER; SURVIVAL RATE; BLOOD; CARCINOMA; COMPARATIVE STUDY; GENETICS; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; SECONDARY; STOMACH NEOPLASMS; TUMOR SUPPRESSOR GENE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENES, APC; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84931259623     PISSN: 00275107     EISSN: 18792871     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2015.05.002     Document Type: Article

References (34)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mather C., Parkin D.M. Estimates of worldwide burden of cancer in 2008. GLOBOCAN 2008. Int. J. Cancer 2008, 127:2893-2917.
2. Hayatt B.G., Paull P.E., Wassef W. Gastric oncology: an update. Curr. Opin. Gastroenterol. 2009, 25:570-578.
3. Tahara E. Molecular mechanism of stomach carcinogenesis. J. Cancer Res. Clin. Oncol. 1993, 119:265-272.
4. Esteller M. Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv. Exp. Med. Biol. 2003, 532:39-49.
5. Baylin S.B. DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol. 2005, 2(Suppl. 1):S4-S11.
6. Nakajima T., Enomoto S., Ushijima T. DNA methylation, a marker for carcinogen exposure and cancer risk. Environ. Health Prev. Med. 2008, 13(1):8-15.
7. Ye T., Chen Y., Fang J. DNA methylation biomarkers in serum of gastric cancer screening. Mini Rev. Med. Chem. 2010, 10:1034-1038.
8. Shivapurkar N., Gazdar A.F. DNA methylation based biomarkers in no-invasive cancer screening. Curr. Mol. Med. 2010, 10(2):123-132.
9. Jahr S., Hentze H., English S., Hardt D., Fackelmayer F.O., Hesch R.D., Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001, 61:1659-1665.
10. Gormally E., Caboux E., Vineis P., Hainaut P. Circulating free DNA in plasma or serum as a biomarker of carcinogenesis: practical aspects and biological significance. Mutat. Res. 2007, 635(2-3):105-117.
11. Jung K., Fleischhacker M., Rabien A. Cell-free DNA in the blood as a solid tumor biomarker - a critical appraisal of the literature. Clin. Chim. Acta 2010, 411(21-22):1611-1624.
12. Zhao Y.F., Zhang Y.G., Tian X.X., Du J., Zheng J. Aberrant methylation of multiple genes in gastric carcinomas. Int. J. Surg. Pathol. 2007, 15(3):242-251.
13. Byun D.S., Lee M.G., Chae K.S., Ryun B.G., Chi S.G. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res. 2001, 61(19):7034-7038.
14. Ghazaleh H.A., Chow R.S., Choo S.L., Pham D., Olessen J.D., Wang R.X., Onyskiw C., Baksh S. 14-3-3 mediated regulation of the tumor suppressor protein, RASSF1A. Apoptosis 2010, 15(2):117-127.
15. Shivakumar L., Minna J., Sakamaki T., Pestell R., White M.A. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol. Cell. Biol. 2002, 22(12):4309-4318.
16. Dallol A., Agathanggelou A., Fenton S.L., Ahmed-Choudhury J., Hesson L., Vos M.D., Clark G.J., Downward J., Maher E.R., Latif F. RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics. Cancer Res. 2004, 64(12):4112-4116.
17. Agathanggelou A., Honorio S., Macartney D.P., Martinez A., Dallol A., Rader J., Fullwood P., Chauhan A., Walker R., Shaw J.A., Hosoe S., Lerman M.I., Minna J.D., Maher E.R., Latif F. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001, 20(12):1509-1518.
18. Wang J., Wang B., Chen X., Bi J. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta analysis. Carcinogenesis 2011, 32(3):411-416.
19. Wang Y.C., Yu Z.H., Liu C., Xu L.Z., Yu W., Lu J., Zhu R.M., Li G.L., Xia X.W., Wei X.W., Ji H.Z., Lu H., Gao W.M., Chen L.B. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J. Gastroenterol. 2008, 14(19):3074-3080.
20. Tamura G., Sato K., Tsuchiya T., Endoh Y., Usuba O., Kimura W., Nishizuka S., Motoyama T. Molecular characterization of undifferentiated-type gastric carcinoma. Lab. Invest. 2001, 81(4):593-598.
21. Maesawa C., Tamura J., Suzuki Y., Oqasawara S., Sakata K., Kashiwaba M., Satodate R. The sequential accumulation of genetic alterations characteristic of colorectal adenoma-carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. J. Pathol. 1995, 176(3):249-258.
22. Wang Z.K., Liu J., Liu C., Wang F.Y., Chen C.Y., Zhang X.H. Hypermethylation of adenomatous poliposis coli gene promoter is associated with novel Wnt signaling pathway in gastric adenomas. J. Gastroenterol. Hepatol. 2012, 27(10):1629-1634.
23. Horii A., Nakatsuru S., Ichii S., Nagase H., Nakamura Y. Multiple forms of the APC gene transcripts and their tissue specific expression. Hum. Mol. Genet. 1993, 2(3):283-287.
24. Perri F., Cotugno R., Piepoli A., Merla A., Quitadamo M., Gentile A., Pilotto A., Annese V., Andriulli A. Aberrant DNA methylation in non neoplastic gastric mucosa of H. Pylori infected patients and effect of eradication. Am. J. Gastroenterol. 2007, 102(7):1361-1371.
25. Hosoya K., Yamashita S., Ando T., Nakajima T., Itoh F., Ushijima T. Adenomatous polyposis coli 1A is likely to be methylated as a passenger in human gastric carcinogenesis. Cancer Lett. 2009, 285(2):182-189.
26. Chen W., Cai F., Zhang B., Zhong X.Y. Strategies of reducing input sample volume for extracting circulating cell-free nuclear DNA and mitochondrial DNA in plasma. Clin. Chem. Lab. Med. 2011, 50(2):261-265.
27. Guo W., Dong Z., Guo Y., Kuang G., Yang Z., Chen Z. Detection of promoter hypermethylation of the CpG island of E-Cadherin in gastric cardiac adenocarcinoma. Eur. J. Med. Res. 2009, 14(10):453-458.
28. Kim H., Kim Y.H., Kim S.E., Kim N.G., Noh S.H., Kim H. Concerted promoter hypermethylation of MGMT, p16INK4A, and E-cadherin in gastric carcinomas with microsatellite instability. J. Pathol. 2003, 200(1):23-31.
29. Shi J., Zhang G., Yao D., Liu W., Wang N., Ji M., He N., Shi B., Hou P. Prognostic significance of aberrant gene methylation in gastric cancer. Am. J. Cancer Res. 2012, 2(1):116-129.
30. Zou X.P., Zhang B., Zhang X.Q., Chen M., Cao J., Liu W.J. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and pancreatic lesions. Hum. Pathol. 2009, 40(11):1534-1542.
31. Balgkouranidou I., Karayiannakis K., Matthaios D., Bolanaki H., Tripsianis G., Tentes A.A., Lianidou E., Chatzaki E., Fiska A., Lambropoulou M., Kolios G., Kakolyris S. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. Clin. Chem. Lab. Med. 2013, 13:1-6.
32. Ye M., Xia B., Guo Q., Zhou F., Zhang X. Association of diminished expression of RASSF1A with promoter methylation in primary gastric cancer from patients of central China. BMC Cancer 2007, 3(7):120.
33. Yao D., Shi J., Shi B., Wang N., Liu W., Zhang G., Ji M., Xu L., He N., Hou P. Quantitative assessment of gene methylation and their impact on clinical outcome in gastric cancer. Clin. Chim. Acta 2012, 413(7-8):787-794.
34. Tan S.H., Ida H., Lau Q.C., Goh B.C., Chieng W.S., Loh M., Ito Y. Detection of promoter hypermethylation in serum samples of cancer patients by methylation specific PCR reaction for tumor suppressor genes including RUNX3. Oncol. Rep. 2007, 18(5):1125-1230.